Atea Pharmaceuticals, Inc. Retained Earnings
Atea Pharmaceuticals, Inc. (AVIR) had Retained Earnings of -$600.94 million as of 2026-06-30, per its 10-Q filed 2026-08-12.
Financial Statements › Balance Sheet › Equity › Equity, Attributable to Parent
us-gaap:RetainedEarningsAccumulatedDeficit · last filed 2026-08-12
- 2026-06-30: Retained Earnings (Accumulated Deficit) -$600.94M.
- 2026-03-31: Retained Earnings (Accumulated Deficit) -$568.01M.
- 2025-12-31: Retained Earnings (Accumulated Deficit) -$522.57M.
- 2025-09-30: Retained Earnings (Accumulated Deficit) -$477.70M.
| Period end | Retained Earnings (Accumulated Deficit) |
|---|---|
| 2026-06-30 | -$600.94M 10-Q · filed 2026-08-12 |
| 2026-03-31 | -$568.01M 10-Q · filed 2026-05-12 |
| 2025-12-31 | -$522.57M 10-Q · filed 2026-08-12 |
| 2025-09-30 | -$477.70M 10-Q · filed 2025-11-12 |
| 2025-06-30 | -$435.65M 10-Q · filed 2025-08-07 |
| 2025-03-31 | -$398.49M 10-Q · filed 2025-05-12 |
| 2024-12-31 | -$364.22M 10-K · filed 2026-03-05 |
| 2024-09-30 | -$330.68M 10-Q · filed 2024-11-07 |
| 2024-06-30 | -$299.53M 10-Q · filed 2024-08-07 |
| 2024-03-31 | -$259.00M 10-Q · filed 2024-05-14 |
| 2023-12-31 | -$195.84M 10-K · filed 2025-03-06 |
| 2023-09-30 | -$156.67M 10-Q · filed 2023-11-08 |
| 2023-06-30 | -$123.53M 10-Q · filed 2023-08-08 |
| 2023-03-31 | -$95.35M 10-Q · filed 2023-05-08 |
| 2022-12-31 | -$59.88M 10-K · filed 2024-02-28 |
| 2022-09-30 | -$25.45M 10-Q · filed 2022-11-07 |
| 2022-06-30 | -$17.38M 10-Q · filed 2022-08-08 |
| 2022-03-31 | $13.95M 10-Q · filed 2022-05-10 |
| 2021-12-31 | $56.03M 10-K · filed 2023-02-28 |
| 2021-09-30 | -$61.10M 10-Q · filed 2021-11-12 |
| 2021-06-30 | -$32.91M 10-Q · filed 2021-08-12 |
| 2021-03-31 | -$34.45M 10-Q · filed 2021-05-13 |
| 2020-12-31 | -$65.16M 10-K · filed 2022-02-28 |
| 2020-09-30 | -$85.82M 10-Q · filed 2020-12-10 |
| 2019-12-31 | -$54.21M 10-K · filed 2021-03-30 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ARS Pharmaceuticals, Inc. (SPRY) | United States | $0.414B | -3.70 |
| RELMADA THERAPEUTICS, INC. (RLMD) | United States | $0.406B | -11.92 |
| Opus Genetics, Inc. (IRD) | United States | $0.406B | -3.16 |
| DiaMedica Therapeutics Inc. (DMAC) | United States | $0.423B | -10.11 |
| Arcturus Therapeutics Holdings Inc. (ARCT) | $0.402B | -2.05 | |
| PROTHENA CORP PUBLIC LTD CO (PRTA) | Ireland | $0.428B | -11.53 |
| GALECTIN THERAPEUTICS INC (GALT) | United States | $0.399B | -11.06 |
| Turn Therapeutics Inc. (TTRX) | United States | $0.397B | -25.68 |
| CYPHERPUNK TECHNOLOGIES INC. (CYPH) | United States | $0.438B | -75.63 |
| Quoin Pharmaceuticals Ltd. (QNRX) | $0.443B | -17.85 |